Are there specific immuno oncology drugs paired with lurbinectedin?

How lurbinectedin fits into immuno-oncology combinations

Lurbinectedin is approved alone for metastatic small cell lung cancer after platinum-based chemotherapy. Its main mechanism blocks RNA polymerase II, causing DNA damage and selective killing of tumor cells. The drug is made by Pharma Mar.

Why companies pair lurbinectedin with checkpoint inhibitors

Companies test lurbinectedin with PD-1/PD-L1 inhibitors because the drug may trigger immunogenic cell death, releasing tumor antigens that can spark an immune response. This logic drives clinical trials combining it with pembrolizumab, atezolizumab, and durvalumab.

How does lurbinectedin plus pembrolizumab perform in trials

A phase 1/2 basket trial led by Pharma Mar showed objective response rates of 46 percent in relapsed/refractory small cell lung cancer and 36 percent in endometrial cancer. The combination was generally well tolerated. The company announced a phase 3 front-line study in small cell lung cancer with pembrolizumab in 2024.

Can lurbinectedin work with atezolizumab

Yes. A study published in 2022 in the Journal of Thoracic Oncology tested lurbinectedin plus atezolizumab in relapsed small cell lung cancer. Response rates reached 20 percent in sensitive disease and 10 percent in resistant disease. The combination showed acceptable safety.

What happens when lurbinectedin is paired with durvalumab

Early data from a 2023 study published in the Journal of Clinical Oncology showed 23 percent response rate in 50 patients with relapsed small cell lung cancer. The combination was also tested in platinum-sensitive ovarian cancer.

When does lurbinectedin’s patent expire

Lurbinectedin’s composition-of-matter patent expires in the US in 2031. Composition of matter is the st st